3D CRISPR screen in prostate cancer cells reveals PARP inhibitor sensitization through TBL1XR1-SMC3 interaction

Poly(ADP-ribose) (PAR) polymerase inhibitors (PARPi) either have been approved or being tested in the clinic for the treatment of a variety of cancers with homologous recombination deficiency (HRD). However, cancer cells can develop resistance to PARPi drugs through various mechanisms, and new bioma...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Huan, Gao, Huanyao, Gu, Yayun, John, August, Wei, Lixuan, Huang, Minhong, Yu, Jia, Adeosun, Adeyemi A., Weinshilboum, Richard M., Wang, Liewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746894/
https://www.ncbi.nlm.nih.gov/pubmed/36523978
http://dx.doi.org/10.3389/fonc.2022.999302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746894/
https://www.ncbi.nlm.nih.gov/pubmed/36523978
http://dx.doi.org/10.3389/fonc.2022.999302

Ejemplares similares